Business Context and Reporting Period
MEDICINOVA INC filed a Form 8-K on March 29, 2013, to disclose a Japanese financial report ("Kessan Tanshin") filed with the Osaka Securities Exchange. This report covers the fiscal year ended December 31, 2012, and provides supplemental financial forecasts for the interim period ending June 30, 2013, and the full fiscal year ending December 31, 2013.
Key Financial Metrics and Guidance
The filing provides forward-looking estimates for 2013 rather than historical results for the current period. The forecasted metrics are as follows:
| Metric | Interim Period (6 Months) | Full Year 2013 |
|---|---|---|
| Revenues | $650,000 | $650,000 |
| Operating Loss | $4,856,000 | $9,921,000 |
| Net Loss | $4,856,000 | $9,921,000 |
| Expected Loss Per Share (Basic & Diluted) | N/A | $0.57 |
Liquidity and Cash Flow: The company anticipates a cash burn of less than $8.0 million for the fiscal year ending December 31, 2013. The filing does not provide specific historical revenue, profit, or debt figures for the year ended December 31, 2012, stating only that the Tanshin is substantially the same as the Form 10-K filed previously.
Material Changes and Unusual Items
The filing does not detail specific material changes in financial performance compared to the prior period, as the primary purpose is to disclose the Japanese report and its forward-looking estimates. The document notes that financial statements denominated in Japanese yen are included as supplementary information, translated at a rate of 92.51 yen per U.S. dollar (as of February 28, 2012).
Risks, Contingencies, and Management Commentary
Management emphasizes that the forecasts are based on assumptions subject to significant risks and uncertainties. Key risks identified include:
- Uncertainty regarding clinical trial results and their predictive value for later stages.
- Risks of delays or failure to obtain regulatory approval.
- Intellectual property rights and enforcement challenges.
- Reliance on third parties for clinical trials and manufacturing.
- Potential cost increases and delays in clinical trial execution.
- Operational risks related to a joint venture in China.
- The availability of funds to complete product development and the ability to raise capital.
The company explicitly states that independent auditors have not compiled or reviewed these forecasted results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the historical financial results for the year ended December 31, 2012, in the Form 10-K filed on March 28, 2013, as this 8-K does not contain those specific numbers.
- Confirm the company's current cash position and runway against the projected cash burn of less than $8.0 million for 2013.
- Review the status of ongoing clinical trials and regulatory filings to assess the validity of the revenue and loss forecasts.
- Monitor the company's capital raising activities given the reliance on external funding for product development.
- Check for updates on the joint venture in China and third-party manufacturing agreements.